OBJECTIVE: We examined whether measures of vitamin D were associated with transitioning to systemic lupus erythematosus (SLE) in individuals at risk for SLE. METHODS: 436 individuals who reported having a relative with SLE but who did not have SLE themselves were evaluated at baseline and again an average of 6.3 (±3.9) years later. Fifty-six individuals transitioned to SLE (≥4 cumulative American College of Rheumatology criteria). 25-Hydroxyvitamin D (25[OH]D) levels were measured by ELISA. Six single-nucleotide polymorphisms in four vitamin D genes were genotyped. Generalised estimating equations, adjusting for correlation within families, were used to test associations between the vitamin D variables and the outcome of transitioning to SLE. RESULTS: Mean baseline 25[OH]D levels (p=0.42) and vitamin D supplementation (p=0.65) were not different between those who did and did not transition to SLE. Vitamin D deficiency (25[OH]D <20 ng/mL) was greater in those who transitioned compared with those who did not transition to SLE (46% vs 33%, p=0.05). The association between 25[OH]D and SLE was modified by CYP24A1 rs4809959, where for each additional minor allele increased 25[OH]D was associated with decreased SLE risk: zero minor alleles (adjusted OR: 1.03, CI 0.98 to 1.09), one minor allele (adjusted OR: 1.01, CI 0.97 to 1.05) and two minor alleles (adjusted OR: 0.91, CI 0.84 to 0.98). Similarly, vitamin D deficiency significantly increased the risk of transitioning to SLE in those with two minor alleles at rs4809959 (adjusted OR: 4.90, CI 1.33 to 18.04). CONCLUSIONS: Vitamin D status and CYP24A1 may have a combined role in the transition to SLE in individuals at increased genetic risk for SLE. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVE: We examined whether measures of vitamin D were associated with transitioning to systemic lupus erythematosus (SLE) in individuals at risk for SLE. METHODS: 436 individuals who reported having a relative with SLE but who did not have SLE themselves were evaluated at baseline and again an average of 6.3 (±3.9) years later. Fifty-six individuals transitioned to SLE (≥4 cumulative American College of Rheumatology criteria). 25-Hydroxyvitamin D (25[OH]D) levels were measured by ELISA. Six single-nucleotide polymorphisms in four vitamin D genes were genotyped. Generalised estimating equations, adjusting for correlation within families, were used to test associations between the vitamin D variables and the outcome of transitioning to SLE. RESULTS: Mean baseline 25[OH]D levels (p=0.42) and vitamin D supplementation (p=0.65) were not different between those who did and did not transition to SLE. Vitamin D deficiency (25[OH]D <20 ng/mL) was greater in those who transitioned compared with those who did not transition to SLE (46% vs 33%, p=0.05). The association between 25[OH]D and SLE was modified by CYP24A1rs4809959, where for each additional minor allele increased 25[OH]D was associated with decreased SLE risk: zero minor alleles (adjusted OR: 1.03, CI 0.98 to 1.09), one minor allele (adjusted OR: 1.01, CI 0.97 to 1.05) and two minor alleles (adjusted OR: 0.91, CI 0.84 to 0.98). Similarly, vitamin D deficiency significantly increased the risk of transitioning to SLE in those with two minor alleles at rs4809959 (adjusted OR: 4.90, CI 1.33 to 18.04). CONCLUSIONS:Vitamin D status and CYP24A1 may have a combined role in the transition to SLE in individuals at increased genetic risk for SLE. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Astrid Rasmussen; Sydney Sevier; Jennifer A Kelly; Stuart B Glenn; Teresa Aberle; Carisa M Cooney; Anya Grether; Ellen James; Jared Ning; Joanne Tesiram; Jean Morrisey; Tiny Powe; Mark Drexel; Wes Daniel; Bahram Namjou; Joshua O Ojwang; Kim L Nguyen; Joshua W Cavett; Jeannie L Te; Judith A James; R Hal Scofield; Kathy Moser; Gary S Gilkeson; Diane L Kamen; Craig W Carson; Ana I Quintero-del-Rio; Maria del Carmen Ballesteros; Marilynn G Punaro; David R Karp; Daniel J Wallace; Michael Weisman; Joan T Merrill; Roberto Rivera; Michelle A Petri; Daniel A Albert; Luis R Espinoza; Tammy O Utset; Timothy S Shaver; Eugene Arthur; Juan-Manuel Anaya; Gail R Bruner; John B Harley Journal: Rheumatology (Oxford) Date: 2010-09-23 Impact factor: 7.580
Authors: Christine G Parks; Aline de Souza Espindola Santos; Medha Barbhaiya; Karen H Costenbader Journal: Best Pract Res Clin Rheumatol Date: 2017-10-21 Impact factor: 4.098
Authors: K A Young; M E Munroe; J M Guthridge; D L Kamen; G S Gilkensen; J B Harley; M H Weisman; D R Karp; D J Wallace; J A James; J M Norris Journal: Lupus Date: 2019-03-07 Impact factor: 2.911
Authors: Samantha Slight-Webb; Carla J Guthridge; Joseph Kheir; Hua Chen; Ly Tran; Tim Gross; Virginia Roberts; Sohail Khan; Michael Peercy; Bobby Saunkeah; Joel M Guthridge; Judith A James Journal: Arthritis Care Res (Hoboken) Date: 2021-10-01 Impact factor: 4.794
Authors: Giulia Frazzei; Ronald F van Vollenhoven; Brigit A de Jong; Sarah E Siegelaar; Dirkjan van Schaardenburg Journal: Front Immunol Date: 2022-06-30 Impact factor: 8.786
Authors: K A Young; M E Munroe; J B Harley; J M Guthridge; D L Kamen; G S Gilkensen; M H Weisman; D R Karp; D J Wallace; J A James; J M Norris Journal: Lupus Date: 2018-05-28 Impact factor: 2.858